-
JMC: Novel STAT3 inhibitor HP590, which is effective for stomach cancer orally
Time of Update: 2022-09-30
On September 14, 2022, the Journal of Medicinal Chemistry, an authoritative journal of international medicinal chemistry, published online, "Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual
-
Biomaterials: Qin Yan's team has developed a new photodynamic therapy to target tumor stem cell ribosomes and achieve tumor ablation
Time of Update: 2022-09-30
Recently, the Qin Yan research group of the Institute of Biophysics of the Chinese Academy of Sciences and the team of professors Wang Tianyu and Jiang Jianzhuang of the University of Science and Technology Beijing published a report in the journal Biomaterials: Amino porphyrin-peptide assemblies induce ribosome damage and cancer stem cell inhibition for an enhanced photodynamic Therapy research papers.
-
Eur Urol Focus: Manual and automatic segmentation radiological characterization of lymph node staging in bladder cancer
Time of Update: 2022-09-30
The researchers performed manual and automatic segmentation of pelvic LNs and extracted a total of 1,004 radioomics features from each LN, training a machine learning model that used histopathological features as a basis to assess PN status.
-
"Research Award You" Chinese oncologists Internet online learning survey, participate in Q&A to win the CSCO guide and other multiple gifts!
Time of Update: 2022-09-30
>> poke here to participate in the > poke here to participate in the > poke here to participate in the > poke here to participate in the > poke here to participate in the > poke here to participate i
-
Zenocutuzumab has shown therapeutic value in patients with metastatic solid tumors of NRG1+
Time of Update: 2022-09-30
On January 7, 2021, Merus NV announced that the FDA has granted Zenocutuzumab (Zeno) Fast-Track Qualification for the treatment of patients with metastatic solid tumors carrying NRG1 gene fusion that progress after receiving standard therapy (NRG1+ cancer).
-
Increased hCG in older men! What's the situation?
Time of Update: 2022-09-30
However, the patient's medical history does not find orchiectomy, and there is no exogenous supplementation of estrogen, how can there be abnormal changes in the above sex hormones?Case studiesInspection Case Study:The patients were older men, but E2 was elevated, T was lower, PRL was mildly elevated, and the results were complex and could not be well explained.
-
Cancer Cell: Shen Hongbing/Hu Zhibin's team published the results of the largest Chinese NSCLC whole genome sequencing to date, revealing rare susceptibility variants in lung cancer
Time of Update: 2022-09-30
Lung cancer is one of the most threatening malignancies in the population to their health and life. In recent years, the incidence of lung cancer has shown signs of increasing significantly in most co
-
J Clin Oncol: Long-term efficacy of Selpercatinib in patients with RET fusion-positive NSCLC
Time of Update: 2022-09-30
Long-term efficacy of SelpercatinibIn the initial treatment of patients, the objective response rate is 84%, and 6% of patients have achieved complete remission.
Long-term efficacy of SelpercatinibIn the initial treatment of patients, the objective response rate is 84%, and 6% of patients have achieved complete remission.
-
More than 30 Nobel laureates have emerged from HHMI, and this world-renowned medical institute was founded by a pilot
Time of Update: 2022-09-30
Guide"People, Not Projects. "This is the purpose of the Howard Hughes Medical Institute (HHMI) in selecting funders. On the homepage of the Howard Hughes Medical Institute (HHMI), there is a striking
-
Cell Discov: Zhao Yao's team at Huashan Hospital and Guo Guoji's team at Zhejiang University have discovered a new drug for targeted treatment of refractory intracranial choroidal tumors
Time of Update: 2022-09-30
On this basis, Professor Zhao Yao's team conducted a Phase I clinical trial in Huashan Hospital, and confirmed in 3 chordoma patients that taking p-EMT inhibitors (YL-13027) can significantly slow tumor growth and maintain a progression-free state for at least 6 months.
-
Gastric Cancer: A deep learning model predicts the efficacy of neoadjuvant chemotherapy for advanced gastric cancer
Time of Update: 2022-09-30
On this basis, the team proposes a new method for predicting efficacy based on the intelligent calculation technology of medical imaging based on the identification problem of neoadjuvant chemotherapy resistance patients in advanced gastric cancer.
-
State Key Laboratory of Market Supervision (Oncology Special Medical Food) inaugurated
Time of Update: 2022-09-30
The development of special medicine has a long way to go in ChinaOn September 6, 2021, the State Administration for Market Supervision and Administration issued the "State Municipal Supervision and Technology Finance Letter [2021] No. 208" document, and the Cancer Special Medical Food Laboratory of Beijing Shijitan Hospital was approved as the Key Laboratory of State Market Regulation.
-
Eur Urol: B7-H3 can be used as a therapeutic target for advanced prostate cancer
Time of Update: 2022-09-30
Recently, researchers from the United Kingdom published an article in Eur Urol investigating the expression of B7-H3 in hormone-sensitive (HSPC) and castration-resistant (CRPC) PC biopsy tissues in the same patient and linked to PC genomics.
-
The law of reading tablets is re-validated - the slowly enlarging mixed ground glass, almost all of them are lung adenocarcinoma
Time of Update: 2022-09-30
At that time, CT, the upper right lung patch shadow, seems to have a frosted glass component.
At that time, CT, the upper right lung patch shadow, seems to have a frosted glass component.
-
Eur Urol: Long-term outcomes of Pembrolizumab plus Olaparib in the treatment of patients with metastatic castration-resistant prostate cancer
Time of Update: 2022-09-30
Aug 2022 Pembrolizumab and olaparib have shown single-agent activity in previously treated patients with metastatic tendency resistant prostate cancer (mCRPC).
Aug 2022 Pembrolizumab and olaparib have shown single-agent activity in previously treated patients with metastatic tendency resistant prostate cancer (mCRPC).
-
NPJ Regenerative Medicine: Xiang Wenpei's team at Huazhong University of Science and Technology established a new method of ovarian tissue transplantation to provide new strategies for protecting women's fertility
Time of Update: 2022-09-30
Recently, Professor Xiang Wenpei's team from the Institute of Reproductive Health of Tongji Medical College of Huazhong University of Science and Technology published a report titled "Multi-biofunctional graphene oxide-enhanced poly-L-lacticacid composite nanofiber scaffolds for ovarian function" in the journal npj Regenerative Medicine A research paper on recovery of transplanted-tissue.
-
Cancer research: Mapping RAS gene mutations based on 60,000 tumors in 51 human cancer types
Time of Update: 2022-09-30
The researchers used Bayesian hierarchical models to estimate the cancer-specific prevalence of KRAS, NRAS, and HRAS allele mutations in codons 12, 13, and 61 in cohorts, stratified by age, race, and sex.
-
Nature Cancer: Zhang Zemin's team revealed the characteristics of tumor-specific T cells and the mechanism of immunotherapy at the multi-cancer level
Time of Update: 2022-09-30
On September 22, 2022, the research group of Zhang Zemin of Peking University's Biomedical Frontier Innovation Center (BIOPIC), School of Life Sciences, and Beijing Future Gene Diagnostics Advanced Innovation Center (ICG) published a report titled "Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to" at Nature Cancer Research paper on immune-checkpoint blockade.
-
LANCET: Cancer Incidence in Children and Adolescents in China Exposed!
Time of Update: 2022-09-30
21/million in areas with high HDI, indicating a significant positive correlation between cancer incidence in children and adolescents and regional socioeconomic status (p<0.
21/million in areas with high HDI, indicating a significant positive correlation between cancer incidence in children and adolescents and regional socioeconomic status (p<0.
-
From research to application: Cancer liquid biopsy technology simplifies cancer detection
Time of Update: 2022-09-30
Introduction: In the long road of life, one-third of people will be diagnosed with cancer, and the early detection of cancer is crucial for cancer treatment, but early screening of cancer is often ove
